<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00211913</url>
  </required_header>
  <id_info>
    <org_study_id>Nabi-1366</org_study_id>
    <nct_id>NCT00211913</nct_id>
  </id_info>
  <brief_title>StaphVAX in Cardiovascular Surgery Patients</brief_title>
  <official_title>A Multicenter, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate Safety and Immunogenicity of StaphVAX速, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine, in Adult Patients Undergoing Cardiovascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nabi Biopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      S. aureus is the most common pathogen encountered in infection associated with cardiovascular
      surgery. StaphVAX速 is a bivalent S. aureus types 5 and 8 vaccine which contains the purified
      capsular polysaccharides (CPS) that have been implicated as a major factor in the
      invasiveness of S. aureus. Immunoprophylaxis by vaccinating against S. aureus prior to
      surgery could provide sufficient antibody concentrations during surgery and during the wound
      healing period so as to decrease the risk of S. aureus infection. This study aims to
      demonstrate the immunogenicity and safety of a single dose of StaphVAX in patients who are
      candidates for cardiovascular surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">January 2006</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotype-specific antibody concentrations</measure>
    <time_frame>6 weeks after the vaccine dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific antibody concentrations</measure>
    <time_frame>at other time points 7-180 days after the vaccine dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>0-180 days after vaccine dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Staphylococcal Infections</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cardiovascular Surgical Procedures</condition>
  <arm_group>
    <arm_group_label>vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose of StaphVAX速</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S. aureus Type 5 &amp; 8 Capsular Polysaccharide Conjugate</intervention_name>
    <description>single IM dose totalling 200 mcg of conjugate</description>
    <arm_group_label>vaccine</arm_group_label>
    <other_name>StaphVAX速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>single IM dose</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Candidate for cardiovascular surgery

          -  Expected to comply with protocol

          -  Negative pregnancy test where appropriate

          -  Written informed consent

        Exclusion Criteria:

          -  Known S. aureus infection in past 3 months

          -  Known infection in the past 2 weeks

          -  Known HIV infection

          -  Pregnancy or breast-feeding

          -  Immunomodulatory drugs

          -  Malignancy or treatment for malignancy within the past six months, other than basal
             cell, localized squamous cell carcinoma of the skin, carcinoma in situ of the cervix,
             or early stage prostate cancer

          -  investigational drugs, vaccines or products in the past 30 days

          -  Hypersensitivity to components of StaphVAX
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Preston Holley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nabi Biopharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 26, 2007</last_update_submitted>
  <last_update_submitted_qc>December 26, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2008</last_update_posted>
  <responsible_party>
    <name_title>Matt Hohenboken, MD, PhD, Executive Director Clinical &amp; Medical Affairs</name_title>
    <organization>Nai Biopharmaceuticals</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

